Assignee
CONTRAFECT CORP
US·16 granted patents·22 pending applications·29 citations·filing 2013–2023
Top patents by PatentIndex Score
38 records- 0197US10988520B2Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2020·Granted Apr 27, 2021·5 cites·20 claims
- 0294US10744189B2Lysin polypeptides active against Gram-negative bacteriaCONTRAFECT CORP·Filed 2016·Granted Aug 18, 2020·8 cites·14 claims
- 0392US11413334B2Lysin polypeptides active against Gram-negative bacteriaCONTRAFECT CORP·Filed 2020·Granted Aug 16, 2022·2 cites·13 claims
- 0486US11773140B2Gram-negative lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof in human serumCONTRAFECT CORP·Filed 2019·Granted Oct 3, 2023·3 cites·47 claims
- 0585US9499594B2Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2013·Granted Nov 22, 2016·6 cites·20 claims
- 0680US2023277617A1Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 0777US9718875B2Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2016·Granted Aug 1, 2017·2 cites·16 claims
- 0877US2023050560A1Lysin polypeptides active against gram-negative bacteriaCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 0975US9889181B2Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2013·Granted Feb 13, 2018·2 cites·12 claims
- 1072US11524046B2Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2019·Granted Dec 13, 2022·0 cites·43 claims
- 1171US12121568B2Identification of lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosaCONTRAFECT CORP·Filed 2018·Granted Oct 22, 2024·1 cites·36 claims
- 1271US2022402984A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 1370US2024018192A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2023·Application pending·0 cites
- 1469US2021128696A1Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2021·Application pending·0 cites
- 1568US11357833B2Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited therebyCONTRAFECT CORP·Filed 2016·Granted Jun 14, 2022·0 cites·17 claims
- 1668US2021008175A1Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 1766US12491245B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2021·Granted Dec 9, 2025·0 cites·23 claims
- 1866US10813983B2Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2013·Granted Oct 27, 2020·0 cites·8 claims
- 1964US2021147498A1Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in pulmonary surfactant and biofilmsCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2061US11246928B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2019·Granted Feb 15, 2022·0 cites·35 claims
- 2161US2021363511A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 2260US2024181022A1Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteriaCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 2359US11827693B2Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2014·Granted Nov 28, 2023·0 cites·36 claims
- 2457US10851401B2Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptidesCONTRAFECT CORP·Filed 2017·Granted Dec 1, 2020·0 cites·16 claims
- 2556US2023277632A1MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIACONTRAFECT CORP·Filed 2021·Application pending·0 cites
- 2654US2021324359A1Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditisCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2754US2022411473A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2853US2022275061A1Therapeutic protein formulations comprising antibodies and uses thereofCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2952US2021330738A1Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteriaCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 3052US2022401514A1Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteriaCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3151US2022160842A1Method of treating infective endocarditisCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3251US2022193186A1Method of treating and preventing bone and joint infectionsCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3350US2017334974A1Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2017·Application pending·0 cites
- 3449US2022023399A1Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereofCONTRAFECT CORP·Filed 2018·Application pending·0 cites
- 3546US2022160843A1Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serumCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3646US2021260070A1Lysin cf-301 resensitizes methicillin-resistant staphylococcus aureua (mrsa) to penicillin derivatives and first generation cephalosporinsCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 3746US2021032294A1MODIFIED PlySs2 LYSINS AND USES THEREOFCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 3838US10639370B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2015·Granted May 5, 2020·0 cites·8 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →